dc.date.accessioned | 2015-10-06T14:29:43Z | |
dc.date.available | 2015-10-06T14:29:43Z | |
dc.date.created | 2015-04-10T22:44:48Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Rustad, Even Holth Dai, Hong Yan Hov, Håkon Coward, Eivind Beisvag, Vidar Myklebost, Ola Hovig, Eivind Nakken, Sigve Vodak, Daniel Meza-Zepeda, Leonardo A. Sandvik, Arne Kristian Wader, Karin Fahl Misund, Kristine Sundan, Anders Aarset, Harald Waage, Anders . BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood Cancer Journal. 2015 | |
dc.identifier.uri | http://hdl.handle.net/10852/46173 | |
dc.description.abstract | In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF V600E by allele-specific real-time PCR (AS-PCR). Positive results were confirmed by immunohistochemistry, Sanger sequencing and, in three patients from whom we had stored purified myeloma cells, whole-exome sequencing. Eleven patients (5.3%) were BRAF V600E mutation positive by AS-PCR and at least one other method. The fraction of mutated cells varied from 4 to 100%. BRAF V600E-positive patients had no characteristic clinical phenotype except for significantly higher levels of serum creatinine (125 versus 86 μmol/l) Seven of eleven patients responded with at least very good partial response to alkylators, immunomodulatory agents or proteasome inhibitors. Progression-free and overall survival were similar in patients with and without the mutation. By this integrated approach, we found that patients with BRAF V600E mutation responded very well to broad acting drugs and there was no relation to prognosis in early-stage myeloma. In particular, a large mutated cell fraction did not correlate with aggressive disease. | en_US |
dc.language | EN | |
dc.language.iso | en | en_US |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis | en_US |
dc.type | Journal article | en_US |
dc.creator.author | Rustad, Even Holth | |
dc.creator.author | Dai, Hong Yan | |
dc.creator.author | Hov, Håkon | |
dc.creator.author | Coward, Eivind | |
dc.creator.author | Beisvag, Vidar | |
dc.creator.author | Myklebost, Ola | |
dc.creator.author | Hovig, Eivind | |
dc.creator.author | Nakken, Sigve | |
dc.creator.author | Vodak, Daniel | |
dc.creator.author | Meza-Zepeda, Leonardo A. | |
dc.creator.author | Sandvik, Arne Kristian | |
dc.creator.author | Wader, Karin Fahl | |
dc.creator.author | Misund, Kristine | |
dc.creator.author | Sundan, Anders | |
dc.creator.author | Aarset, Harald | |
dc.creator.author | Waage, Anders | |
cristin.unitcode | 185,90,0,0 | |
cristin.unitname | Universitetet i Oslo | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1236661 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Blood Cancer Journal&rft.volume=&rft.spage=&rft.date=2015 | |
dc.identifier.jtitle | Blood Cancer Journal | |
dc.identifier.volume | 5 | |
dc.identifier.doi | http://dx.doi.org/10.1038/bcj.2015.24 | |
dc.identifier.doi | 10.1038/bcj.2015.24 | |
dc.identifier.urn | URN:NBN:no-50365 | |
dc.type.document | Tidsskriftartikkel | en_US |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 2044-5385 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/46173/2/bcj201524a.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | e299 | |